Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT01330173
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
Vismodegib in Treating Patients With Advanced Chondrosarcomas
- Conditions
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT01267955
- Locations
- 🇫🇷
Centre Oscar Lambert, Lille, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷Hopital De La Timone, Marseille, France
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT01239316
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01209143
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT01201915
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT01195415
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
- Conditions
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT01174264
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT01163084
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT01154452
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01071564
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Michigan University Hospital, Ann Arbor, Michigan, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.